02.04.14
Waltham, Mass.-based NeuroMetrix Inc., a medical device company focused on the treatment and management of the neurological complications of diabetes, has entered national distribution agreement with orthopedic device company DJO Global for the Sensus pain management system. Sensus is a wearable, non-invasive electrical nerve stimulator that offers patients a reported fast-acting, non-narcotic option for relief from chronic pain. The device is lightweight and can be worn during the day while remaining active, or at night while sleeping. It is optimally designed for people with diabetes that suffer from chronic pain. The most common cause of such pain is painful diabetic neuropathy (PDN), which affects up to 5 million people in the United States alone.
The Recovery Sciences division of DJO makes electrical stimulation and other orthopedic products used for pain management, orthopedic rehabilitation, physical therapy, fitness and sport performance enhancement. It deploys a direct U.S. sales force. Recovery Sciences will market Sensus primarily to pain management and podiatry clinics, as well as in endocrinology, internal medicine, primary care and neurology clinics. This agreement follows a Sensus market pilot conducted in the second half of 2013.
“Sensus nicely compliments the Recovery Sciences electrotherapy product offerings for pain management”, said Rick Rioles, senior vice president, business development, Recovery Sciences division, DJO Global. “We believe that the diabetic pain market represents a growth opportunity for electrotherapy as it addresses important unmet clinical needs. We are impressed by the Sensus technology and its status as the only transcutaneous electrical nerve stimulator cleared for use during sleep. We believe it will have strong appeal in our target markets.”
“We believe that the national reach, talent, and subject matter expertise of the Recovery Sciences sales force will play a key role in accelerating Sensus adoption in the U.S. market,” said Shai N. Gozani, M.D., Ph.D., president and CEO of NeuroMetrix. “We believe that this partnership will substantially expand patient access to the clinical benefits of Sensus pain therapy.”
DJO’s Recovery Sciences has been under new leadership since early January. Sharon Wolfington, a 20 year medtech sales, marketing and management vet, is the division’s new president.
Wolfington joined DJO Global from Stryker, most recently as president of Stryker’s performance solutions business, and was responsible for building and leading a startup business within Stryker to deliver systems and services to assist hospitals, patients, payors and surgeons focused on meeting their clinical, financial and operational performance goals. Previously she held the position of vice president and general manager of Stryker Global Trauma and Extremities, demonstrating many consecutive years of leading sales growth. Wolfington joined Stryker in 2001 as director of sales for Stryker Biotech. Prior to Stryker, she held several roles at Biomet/EBI Medical Systems. Wolfington has completed the Harvard Business School Advanced Management Program, and has a Bachelor of Arts degree in nutrition science from Miami University.
“Sharon brings a wealth of experience and proven track record to DJO Global,” said Mike Mogul, DJO global president and CEO. “We look forward to her contribution to the executive management team and expect her broad experiences to make a terrific impact at DJO Global.”
The Recovery Sciences division of DJO makes electrical stimulation and other orthopedic products used for pain management, orthopedic rehabilitation, physical therapy, fitness and sport performance enhancement. It deploys a direct U.S. sales force. Recovery Sciences will market Sensus primarily to pain management and podiatry clinics, as well as in endocrinology, internal medicine, primary care and neurology clinics. This agreement follows a Sensus market pilot conducted in the second half of 2013.
“Sensus nicely compliments the Recovery Sciences electrotherapy product offerings for pain management”, said Rick Rioles, senior vice president, business development, Recovery Sciences division, DJO Global. “We believe that the diabetic pain market represents a growth opportunity for electrotherapy as it addresses important unmet clinical needs. We are impressed by the Sensus technology and its status as the only transcutaneous electrical nerve stimulator cleared for use during sleep. We believe it will have strong appeal in our target markets.”
“We believe that the national reach, talent, and subject matter expertise of the Recovery Sciences sales force will play a key role in accelerating Sensus adoption in the U.S. market,” said Shai N. Gozani, M.D., Ph.D., president and CEO of NeuroMetrix. “We believe that this partnership will substantially expand patient access to the clinical benefits of Sensus pain therapy.”
DJO’s Recovery Sciences has been under new leadership since early January. Sharon Wolfington, a 20 year medtech sales, marketing and management vet, is the division’s new president.
Wolfington joined DJO Global from Stryker, most recently as president of Stryker’s performance solutions business, and was responsible for building and leading a startup business within Stryker to deliver systems and services to assist hospitals, patients, payors and surgeons focused on meeting their clinical, financial and operational performance goals. Previously she held the position of vice president and general manager of Stryker Global Trauma and Extremities, demonstrating many consecutive years of leading sales growth. Wolfington joined Stryker in 2001 as director of sales for Stryker Biotech. Prior to Stryker, she held several roles at Biomet/EBI Medical Systems. Wolfington has completed the Harvard Business School Advanced Management Program, and has a Bachelor of Arts degree in nutrition science from Miami University.
“Sharon brings a wealth of experience and proven track record to DJO Global,” said Mike Mogul, DJO global president and CEO. “We look forward to her contribution to the executive management team and expect her broad experiences to make a terrific impact at DJO Global.”